DK1058558T3 - Rekombinante og adjuverede vacciner mod influenzavirus og herpesvirus - Google Patents

Rekombinante og adjuverede vacciner mod influenzavirus og herpesvirus

Info

Publication number
DK1058558T3
DK1058558T3 DK99937879T DK99937879T DK1058558T3 DK 1058558 T3 DK1058558 T3 DK 1058558T3 DK 99937879 T DK99937879 T DK 99937879T DK 99937879 T DK99937879 T DK 99937879T DK 1058558 T3 DK1058558 T3 DK 1058558T3
Authority
DK
Denmark
Prior art keywords
recombinant
herpes virus
virus vaccines
adjuvanted influenza
adjuvanted
Prior art date
Application number
DK99937879T
Other languages
Danish (da)
English (en)
Inventor
Jean-Christophe Franc Audonnet
Jules Maarten Minke
Original Assignee
Merial Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Sas filed Critical Merial Sas
Application granted granted Critical
Publication of DK1058558T3 publication Critical patent/DK1058558T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK99937879T 1998-03-03 1999-03-01 Rekombinante og adjuverede vacciner mod influenzavirus og herpesvirus DK1058558T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9802800A FR2775601B1 (fr) 1998-03-03 1998-03-03 Vaccins vivants recombines et adjuves
PCT/FR1999/000453 WO1999044633A1 (fr) 1998-03-03 1999-03-01 Vaccins vivants recombines et adjuves

Publications (1)

Publication Number Publication Date
DK1058558T3 true DK1058558T3 (da) 2005-06-06

Family

ID=9523775

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99937879T DK1058558T3 (da) 1998-03-03 1999-03-01 Rekombinante og adjuverede vacciner mod influenzavirus og herpesvirus

Country Status (22)

Country Link
US (2) US6713068B1 (hu)
EP (1) EP1058558B1 (hu)
JP (1) JP2002505300A (hu)
KR (1) KR20010041507A (hu)
CN (2) CN1263511C (hu)
AR (1) AR018135A1 (hu)
AT (1) ATE287728T1 (hu)
AU (1) AU762479B2 (hu)
BR (1) BR9908496A (hu)
CA (1) CA2321903C (hu)
DE (1) DE69923434T2 (hu)
DK (1) DK1058558T3 (hu)
ES (1) ES2237931T3 (hu)
FR (1) FR2775601B1 (hu)
HU (1) HU228431B1 (hu)
IL (1) IL137872A0 (hu)
NZ (1) NZ506370A (hu)
PL (1) PL197405B1 (hu)
PT (1) PT1058558E (hu)
TW (1) TW592700B (hu)
WO (1) WO1999044633A1 (hu)
ZA (1) ZA991662B (hu)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804026B1 (fr) * 2000-01-21 2004-06-11 Merial Sas Vaccination contre l'herpesvirose canine et vaccins
US6551598B2 (en) 2000-01-21 2003-04-22 Merial Vaccination against canine herpesvirosis and vaccines therefor
US20040105871A1 (en) * 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
US20150231227A1 (en) * 2000-03-02 2015-08-20 Emory University Compositions and methods for generating an immune response
BR0111366A (pt) * 2000-05-24 2003-05-20 Merial Sas Vacina de poxvìrus recombinante do vìrus da sìndrome respiratória e reprodutiva de porcino (prrsv)
US7627145B2 (en) * 2000-09-06 2009-12-01 Hitachi, Ltd. Personal identification device and method
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US20040037848A1 (en) * 2001-04-06 2004-02-26 Audonnet Jean-Christophe Francis Recombinant vaccine against West Nile Virus
US7740863B2 (en) * 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
CA2570218C (en) 2004-06-15 2015-11-10 The New York Blood Center, Inc. Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
ES2620789T3 (es) 2005-08-15 2017-06-29 Altimmune Inc. Inmunización de aves por administración de vacunas con vectores no replicantes
US20080241184A1 (en) * 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7425336B2 (en) * 2005-08-25 2008-09-16 Mevial Limited Canine influenza vaccines
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US9598462B2 (en) 2012-01-26 2017-03-21 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
ES2673046T3 (es) 2006-09-26 2018-06-19 Infectious Disease Research Institute Composición de vacuna que contiene un adyuvante sintético
UA100370C2 (uk) 2006-12-11 2012-12-25 Мериал Лимитед Спосіб вакцинації птахів проти salmonella
TW200907058A (en) * 2007-05-30 2009-02-16 Wyeth Corp Raccoon poxvirus expressing rabies glycoproteins
CL2008001806A1 (es) * 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
WO2009029686A1 (en) 2007-08-27 2009-03-05 Longhorn Vaccines & Diagnostics Llc Immunogenic compositions and methods
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
AU2008343745B2 (en) 2007-10-01 2012-05-10 Longhorn Vaccines & Diagnostics Llc Biological specimen collection and transport system and methods of use
GB0805356D0 (en) * 2008-03-25 2008-04-30 Isis Innovation Vaccine adjuvant composition
BRPI0915605B8 (pt) 2008-05-08 2021-09-08 The Government Of The Us Secretary Of The Dept Of Healt & Human Services Vacina de leishmania usando imunógeno salivar de mosca tipo borrachudo
KR101719005B1 (ko) * 2008-10-24 2017-03-22 메리얼 인코포레이티드 아프리카 마역 바이러스에 대한 백신
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
US20130197612A1 (en) * 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
CN103596586A (zh) 2011-04-08 2014-02-19 免疫设计公司 免疫原性组合物及使用所述组合物诱导体液和细胞免疫反应的方法
WO2013012446A1 (en) 2011-07-20 2013-01-24 Merial Limited Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene
DK2741740T3 (en) 2011-08-12 2017-06-06 Merial Inc VACUUM-SUPPORTED CONSERVATION OF BIOLOGICAL PRODUCTS, IN PARTICULAR OF VACCINES
PT2811981T (pt) 2012-02-07 2019-06-12 Infectious Disease Res Inst Formulações adjuvantes melhoradas que compreendem os agonistas de tlr4 e os seus métodos de utilização
EP2814506B1 (en) 2012-02-14 2018-11-28 Merial, Inc. Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom
ES2711878T3 (es) 2012-03-20 2019-05-08 Merial Inc Vacuna contra el virus del herpes equino 1 recombinante que contiene glicoproteína C mutada y usos de la misma
CN107540730B (zh) 2012-05-16 2021-07-16 免疫设计公司 用于hsv-2的疫苗
AU2013308623B2 (en) 2012-08-30 2017-03-02 Merial, Inc. Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins
EA032326B1 (ru) 2013-04-18 2019-05-31 Иммьюн Дизайн Корп. Монотерапия gla для применения в лечении рака
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
CA2948845C (en) 2014-05-14 2022-05-31 Merial, Inc. Methods for freeze-drying and rehydrating biologics
EP3757211A1 (en) 2014-12-19 2020-12-30 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
CA2985652C (en) 2015-05-14 2020-03-10 Gerald W. FISHER Rapid methods for the extraction of nucleic acids from biological samples
US10835585B2 (en) 2015-05-20 2020-11-17 The Broad Institute, Inc. Shared neoantigens
KR20180035743A (ko) 2015-07-31 2018-04-06 필립모리스 프로덕츠 에스.에이. 둥근 또는 경사진 코너를 갖는 용기를 형성하기 위한 주름진 블랭크
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
MX2018014086A (es) 2016-05-16 2019-09-18 Infectious Disease Res Inst Formulacion que contiene agonista tlr y metodos de uso.
KR20220165789A (ko) 2016-06-01 2022-12-15 액세스 투 어드밴스드 헬스 인스티튜트 사이징제를 함유하는 나노명반 입자
US11554170B2 (en) 2016-06-17 2023-01-17 Sanofi Pasteur Sa Immunogenic formulations comprising linear or branched polyacrylic acid polymer adjuvants
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
AU2018330165A1 (en) 2017-09-08 2020-04-02 Access To Advanced Health Institute Liposomal formulations comprising saponin and methods of use
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
CN110846284B (zh) * 2019-11-07 2020-12-29 衡阳师范学院 一种犬细小病毒CPV-HuN1703株及其应用
CN111500633B (zh) * 2020-04-07 2022-09-16 军事科学院军事医学研究院军事兽医研究所 基于基因编辑技术的重组金丝雀痘病毒构建方法
AU2021280261A1 (en) 2020-05-26 2023-01-19 Dionis Therapeutics, Inc. Nucleic acid artificial mini-proteome libraries
CN113308441B (zh) * 2021-06-02 2022-05-10 华中农业大学 一株猫疱疹病毒i型病毒株及其应用
WO2023076733A1 (en) 2021-11-01 2023-05-04 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3790665A (en) 1968-02-23 1974-02-05 Haver Lockhart Labor Inc Injectable adjuvant,method of preparing same and compositions including such adjuvant
US3651213A (en) 1969-05-29 1972-03-21 Monsanto Co Method for the immunization of a living animal body against viral disease
US3919411A (en) 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US3920811A (en) * 1972-12-22 1975-11-18 Cutter Lab Adjuvant compositions
US3869546A (en) * 1972-12-22 1975-03-04 Cutter Lab Adjuvant compositions and medicinal mixtures comprising them
US4309413A (en) 1979-01-22 1982-01-05 Monsanto Company Method of producing immune response by administering polymeric composition
US4567042A (en) 1983-06-15 1986-01-28 American Home Products Corporation Inactivated canine coronavirus vaccine
US4920213A (en) * 1985-06-20 1990-04-24 Biotechnology Research Partners, Ltd. Method and compositions useful in preventing equine influenza
JPS62201575A (ja) * 1986-02-27 1987-09-05 Shionogi & Co Ltd 家禽用インフルエンザ生ワクチン
US5731188A (en) * 1986-11-20 1998-03-24 Syntro Corporation Recombinant equine herpesviruses
ES2052685T3 (es) * 1987-03-17 1994-07-16 Akzo Nv Metodo para producir un adyuvante libre.
US5843456A (en) * 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
EP0532833A1 (en) * 1991-05-28 1993-03-24 Miles Inc. Vaccine for equine rhinopneumonitis
ATE152915T1 (de) * 1991-11-29 1997-05-15 Viagene Inc Immuntherapeutische vektorkonstrukte gegen krebs
FR2700957B1 (fr) * 1993-01-29 1995-03-03 Seppic Sa Composition de vaccin sous-unitaire recombinant vivant et procédé de préparation.
EP0688205A1 (en) 1993-03-11 1995-12-27 Secretech, Inc. Polymeric mucoadhesives in the delivery of immunogens at mucosal surfaces
JPH07170982A (ja) * 1993-09-09 1995-07-11 Nisshin Oil Mills Ltd:The ワクチンおよびその製造方法
WO1995030437A1 (en) * 1994-05-10 1995-11-16 American Home Products Corporation Improved modified live brsv vaccine
US6300118B1 (en) 1995-06-07 2001-10-09 American Home Products Corporation Plasmids comprising a genetically altered feline immunodeficiency virus genome
US5849303A (en) 1995-06-07 1998-12-15 American Home Products Corporation Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection
US5820869A (en) * 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
ZA97452B (en) * 1996-01-25 1997-08-15 Trinity College Dublin Streptococcus equi vaccine.
DE19612967A1 (de) * 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
FR2750865B1 (fr) * 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
FR2751226B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
US6004777A (en) * 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6044777A (en) * 1998-02-09 2000-04-04 Walsh; Michael J. Composite metal safe and method of making

Also Published As

Publication number Publication date
PT1058558E (pt) 2005-06-30
CA2321903C (en) 2011-05-31
AR018135A1 (es) 2001-10-31
PL342820A1 (en) 2001-07-02
CA2321903A1 (en) 1999-09-10
ATE287728T1 (de) 2005-02-15
ZA991662B (en) 2000-10-12
PL197405B1 (pl) 2008-03-31
EP1058558A1 (fr) 2000-12-13
TW592700B (en) 2004-06-21
FR2775601A1 (fr) 1999-09-10
US6713068B1 (en) 2004-03-30
KR20010041507A (ko) 2001-05-25
CN1263511C (zh) 2006-07-12
US20060057163A1 (en) 2006-03-16
FR2775601B1 (fr) 2001-09-21
ES2237931T3 (es) 2005-08-01
HUP0101207A3 (en) 2003-10-28
NZ506370A (en) 2003-07-25
BR9908496A (pt) 2000-12-05
AU3257199A (en) 1999-09-20
JP2002505300A (ja) 2002-02-19
AU762479B2 (en) 2003-06-26
EP1058558B1 (fr) 2005-01-26
IL137872A0 (en) 2001-10-31
CN1291899A (zh) 2001-04-18
HU228431B1 (en) 2013-03-28
DE69923434T2 (de) 2006-01-05
HUP0101207A2 (hu) 2001-08-28
WO1999044633A1 (fr) 1999-09-10
US7507416B2 (en) 2009-03-24
DE69923434D1 (de) 2005-03-03
CN1846786A (zh) 2006-10-18

Similar Documents

Publication Publication Date Title
DK1058558T3 (da) Rekombinante og adjuverede vacciner mod influenzavirus og herpesvirus
GB2337755B (en) Virus vaccine
ZA9711247B (en) Recombinant live avian vaccine using as vector the avian infectious laryngotracheitis virus
IL148673A0 (en) Intranasal influenza virus vaccine
ZA975618B (en) Avian recombinant live vaccine using as vector the avian infectious laryngotrachetis virus
AU4932601A (en) Recombinant parainfluenza virus expression systems and vaccines
IL123961A (en) Influenza vaccine
NL300311I2 (nl) Adjuvanssytemen en vaccins
AU4869299A (en) Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
AU6217798A (en) Avian recombinant live vaccine using, as vector, the avian infectious laryngotracheitis virus
PL354090A1 (en) Peptides that block viral infectivity and methods of use thereof
AU2328397A (en) Recombinant live feline immunodeficiency virus and proviral dna vaccines
GB2264949B (en) Measles virus recombinant poxvirus vaccine
IL131212A0 (en) Recombinant virus and live-virus vaccines
DK1248650T3 (da) Forbedrede DNA-vacciner til bovint herpesvirus 1
DK1372712T3 (da) Vaccine mod equint herpesvirus
AU2946395A (en) Recombinant infectious laryngotracheitis virus and vaccine
GB9702990D0 (en) Virus vaccine
IL147841A0 (en) Recombinant hsv-1 and live viral vaccines
HUP0202738A3 (en) Equine herpes virus temperature sensitive mutant and live vaccine thereof
ZA919198B (en) Measles virus recombinant poxvirus vaccine
GB9620856D0 (en) Virus vaccine
SI1155119T1 (sl) Virusno cepivo z deletiranim BHV-1 genom
AU6051396A (en) Measles virus recombinant poxvirus vaccine
PT841943E (pt) Virus herpeticos avirulentos uteis como agentes tumoricidas e vacinas